Oncolytics up 12% premarket on modest volume

|About: Oncolytics Biotech Inc. (ONCYF)|By:, SA News Editor

Shares of Oncolytics Biotech (ONCY) are poised for a gap up this morning in response to positive Phase 2 clinical trial results for REOLYSIN.

The 165-patient study REO 018 compared the use of REOLYSIN in combination with carboplatin and paclitaxel for the treatment of patients with second-line platinum-refractory taxane-naive head and neck cancers with carboplatin, paclitaxel and placebo.

In the intent-to-treat analysis of 118 loco-regional patients, the REOLYSIN group showed a statically significant improvement in OS and PFS.